Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Five Prime Therapeutics’ pancreatic cancer combo misses endpoint

Opdivo
The trial assessed cabiralizumab plus Opdivo with or without chemotherapy. Credit: kennejima.